Results 181 to 190 of about 47,999 (247)

Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Phoebe Wellmann, Jana Zschüntzsch, Michael P. Schön, Rotraut Mössner   +3 more
wiley   +1 more source

Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Vitiligo is a chronic autoimmune disease with heterogeneous clinical presentations. This study analysed 399 patients using hierarchical clustering and identified five phenotypes based on clinical characteristics and lesion distribution. Two groups exhibited high disease activity and extensive involvement.
Laura Galissi, Tristan Benoît, Ribal Merhi, Claire Drullion, Nicolas Andreu, Khaled Ezzedine, Thomas Darde, Katia Boniface, Julien Seneschal   +8 more
wiley   +1 more source

From plaques to pigment: Eruptive lentiginosis in resolving psoriatic plaques after biologic therapy. [PDF]

JAAD Case Rep
Choe S, Patel AB, Phong C, Yale K, Golbari NM, Zachary CB, Min MS.   +6 more
europepmc   +1 more source

Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer, Johannes Mohr, Michael P. Schön, Rotraut Mössner   +3 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

How to select the correct patients for home phototherapy of neonatal hyperbilirubinaemia-a retrospective population-based implementation study. [PDF]

Eur J Pediatr
Pettersson M, Lai C, Ohlin A.
europepmc   +1 more source

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

International Journal of Dermatology, EarlyView.
Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis   +8 more
wiley   +1 more source

Impact of weight‐loss interventions on psoriasis severity: A systematic review and meta‐analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Weight‐loss interventions were associated with clinically and statistically significant improvements in psoriasis severity (PASI and PASI 75) and quality of life (DLQI). These findings support the role of weight‐loss interventions as effective adjuncts to medical therapy and their integration into holistic psoriasis care.
Sarah Morrow, Poppy Hawkins, Christopher E. M. Griffiths, Thanasis G. Tektonidis, Eli Harriss, Jadine Scragg, Susan Jebb   +6 more
wiley   +1 more source

Tumoral Stage of Mycosis Fungoides, Misdiagnosed With Wells Syndrome and Langerhans Cell Histiocytosis Histologically: A Challenging Case and Review of the Literature. [PDF]

Cancer Rep (Hoboken)
Vahabi SM, Montazeri S, Pourgholi E, Bahramian S, Ghanadan A, Hesari KK, Etesami I.   +6 more
europepmc   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source